Accordingly, treatment of C57BL/6 mice bearing B16F10 tumors with IL-2ICx selective for trimeric IL-2Rαβγ increased the frequency of GZMB+ and KLRK1/NGK2D+ cells (corresponding to the better effector T cells) among splenic and tumor-infiltrating CD8+ T cells evaluated by flow cytometry [3]. The gene discussed is CD8A; the disease is neoplasm.